Compare Suven Life Sciences with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE SCIENCES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE SCIENCES CIPLA SUVEN LIFE SCIENCES/
CIPLA
 
P/E (TTM) x -81.5 32.7 - View Chart
P/BV x 1.3 4.6 27.7% View Chart
Dividend Yield % 1.8 0.4 405.3%  

Financials

 SUVEN LIFE SCIENCES   CIPLA
EQUITY SHARE DATA
    SUVEN LIFE SCIENCES
Mar-19
CIPLA
Mar-20
SUVEN LIFE SCIENCES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs338586 57.7%   
Low Rs169357 47.5%   
Sales per share (Unadj.) Rs52.1207.0 25.2%  
Earnings per share (Unadj.) Rs6.818.6 36.7%  
Cash flow per share (Unadj.) Rs8.633.2 25.8%  
Dividends per share (Unadj.) Rs1.504.00 37.5%  
Dividend yield (eoy) %0.60.8 69.7%  
Book value per share (Unadj.) Rs65.3195.5 33.4%  
Shares outstanding (eoy) m127.28806.35 15.8%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x4.92.3 213.7%   
Avg P/E ratio x37.125.3 146.5%  
P/CF ratio (eoy) x29.614.2 208.2%  
Price / Book Value ratio x3.92.4 161.1%  
Dividend payout %22.021.5 102.1%   
Avg Mkt Cap Rs m32,272379,912 8.5%   
No. of employees `0001.125.8 4.2%   
Total wages/salary Rs m66130,270 2.2%   
Avg. sales/employee Rs Th6,132.26,459.6 94.9%   
Avg. wages/employee Rs Th611.11,171.2 52.2%   
Avg. net profit/employee Rs Th803.5580.2 138.5%   
INCOME DATA
Net Sales Rs m6,635166,949 4.0%  
Other income Rs m2423,442 7.0%   
Total revenues Rs m6,877170,391 4.0%   
Gross profit Rs m1,60432,060 5.0%  
Depreciation Rs m22111,747 1.9%   
Interest Rs m381,974 1.9%   
Profit before tax Rs m1,58721,782 7.3%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7186,312 11.4%   
Profit after tax Rs m86914,995 5.8%  
Gross profit margin %24.219.2 125.9%  
Effective tax rate %45.229.0 156.1%   
Net profit margin %13.19.0 145.9%  
BALANCE SHEET DATA
Current assets Rs m6,232117,038 5.3%   
Current liabilities Rs m1,49043,931 3.4%   
Net working cap to sales %71.543.8 163.2%  
Current ratio x4.22.7 157.0%  
Inventory Days Days8696 90.3%  
Debtors Days Days8385 97.1%  
Net fixed assets Rs m4,043107,424 3.8%   
Share capital Rs m1271,613 7.9%   
"Free" reserves Rs m8,183156,018 5.2%   
Net worth Rs m8,310157,630 5.3%   
Long term debt Rs m1823,693 0.1%   
Total assets Rs m10,389236,626 4.4%  
Interest coverage x43.112.0 358.1%   
Debt to equity ratio x00.2 1.4%  
Sales to assets ratio x0.60.7 90.5%   
Return on assets %8.77.2 121.8%  
Return on equity %10.59.5 110.0%  
Return on capital %19.512.8 152.0%  
Exports to sales %033.0 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,175 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62256,036 10.0%   
Fx outflow Rs m1,7996,764 26.6%   
Net fx Rs m3,82249,272 7.8%   
CASH FLOW
From Operations Rs m35630,685 1.2%  
From Investments Rs m-2791,040 -26.8%  
From Financial Activity Rs m-225-29,488 0.8%  
Net Cashflow Rs m-1482,340 -6.3%  

Share Holding

Indian Promoters % 63.4 16.0 396.3%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.0 12.2 -  
FIIs % 0.0 23.7 -  
ADR/GDR % 0.0 1.1 -  
Free float % 36.5 26.2 139.3%  
Shareholders   37,287 161,166 23.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE SCIENCES With:   JUBILANT PHARMOVA   DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare SUVEN LIFE SCIENCES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Trades Higher, 5 Factors Behind the Stock Market Crash, Shriram Properties IPO, and Buzzing Stocks Today(Pre-Open)

Indian share markets crashed yesterday as fears that the government could go for stricter lockdowns to curb the second wave of Covid-19.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SCIENCES SHARE PRICE


Apr 12, 2021 (Close)

TRACK SUVEN LIFE SCIENCES

  • Track your investment in SUVEN LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFE SCIENCES

SUVEN LIFE SCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFE SCIENCES WITH

MARKET STATS